Immunic Inc. (NASDAQ: IMUX) announced the presentation of additional data from its Phase 2 CALLIPER trial evaluating vidofludimus calcium in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE